{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:06:34Z","timestamp":1768316794484,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clml.2018.02.011","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T12:21:44Z","timestamp":1518870104000},"page":"235-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review"],"prefix":"10.1016","volume":"18","author":[{"given":"Charlotte","family":"Cosemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9nedith","family":"Oben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Arijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Dani\u00ebls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-7729","authenticated-orcid":false,"given":"Jeroen","family":"Declercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Vanhees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Froyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Mebis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Rummens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.02.011_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2018.02.011_bib2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.011_bib3","author":"Organization WH"},{"key":"10.1016\/j.clml.2018.02.011_bib4","author":"Cancer Research UK"},{"key":"10.1016\/j.clml.2018.02.011_bib5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.011_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bjh.13620","article-title":"Time to redefine Myeloma","volume":"171","author":"Pratt","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.011_bib7","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2018.02.011_bib8","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.18632\/oncotarget.4434","article-title":"Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation","volume":"6","author":"Lionetti","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.02.011_bib9","first-page":"157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J\u00a0Biomed Biotechnol"},{"key":"10.1016\/j.clml.2018.02.011_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2018.02.011_bib11","series-title":"Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ)","author":"Institute NC","year":"2016"},{"key":"10.1016\/j.clml.2018.02.011_bib12","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3109\/10428194.2010.525725","article-title":"Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"51","author":"Mailankody","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.011_bib13","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib14","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/ehm.10.13","article-title":"Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma","volume":"3","author":"Weiss","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2018.02.011_bib16","first-page":"798","article-title":"Unusual myelomas: a review of IgD and IgE variants","volume":"27","author":"Pandey","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2018.02.011_bib17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.011_bib18","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.14694\/EdBook_AM.2015.35.e493","article-title":"Multiple myeloma: is it time for biomarker-driven therapy?","author":"Bhutani","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2018.02.011_bib19","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2017.1334124","article-title":"Diagnosis and management of smoldering multiple myeloma: the razor\u2019s edge between clonality and cancer","volume":"59","author":"Muchtar","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.02.011_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A\u00a0long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.02.011_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib23","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/leu.2012.189","article-title":"Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS","volume":"27","author":"Katzmann","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.011_bib25","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejim.2012.01.012","article-title":"Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma","volume":"23","author":"Tsirakis","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clml.2018.02.011_bib27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2795.x","article-title":"Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies","volume":"77","author":"Quartarone","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.02.011_bib28","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.02.011_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.leukres.2006.06.012","article-title":"Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression","volume":"31","author":"Kline","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.02.011_bib30","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A\u00a0reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2018.02.011_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.011_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2141.2003.04589.x","article-title":"Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications","volume":"123","author":"Saeki","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.011_bib33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.011_bib34","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1038\/bcj.2016.19","article-title":"Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)","volume":"6","author":"Papanikolaou","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.02.011_bib35","author":"International Myeloma Foundation"},{"key":"10.1016\/j.clml.2018.02.011_bib36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2015.65","article-title":"The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma","volume":"29","author":"Papanikolaou","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.011_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2018.02.011_bib38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/leu.2013.244","article-title":"Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance","volume":"28","author":"Hillengass","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.011_bib39","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1158\/1078-0432.CCR-08-2310","article-title":"Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation","volume":"15","author":"Hillengass","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.02.011_bib40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.011_bib41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/PAS.0000000000000213","article-title":"MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS)","volume":"38","author":"Xiao","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2018.02.011_bib42","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.011_bib43","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/gcc.22290","article-title":"Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"54","author":"Nagoshi","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2018.02.011_bib44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.12689","article-title":"Nestin expression throughout multistep pathogenesis of multiple myeloma","volume":"164","author":"Svachova","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.02.011_bib45","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2003-12-4114","article-title":"Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines","volume":"104","author":"Houde","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib46","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib47","first-page":"1521","article-title":"CD28, a marker associated with tumoral expansion in multiple myeloma","volume":"4","author":"Robillard","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.02.011_bib48","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","article-title":"Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression","volume":"104","author":"Kumar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib49","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib50","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib51","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-09-0040","article-title":"Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma","volume":"15","author":"Ria","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.02.011_bib52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Jungbluth","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib53","first-page":"2","article-title":"Prognostic impact of cancer\/testis antigen expression in advanced stage multiple myeloma patients","volume":"8","author":"Andrade","year":"2008","journal-title":"Cancer Immun"},{"key":"10.1016\/j.clml.2018.02.011_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","article-title":"Molecular mechanisms in multiple myeloma drug resistance","volume":"69","author":"Nikesitch","year":"2016","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clml.2018.02.011_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/leu.2013.6","article-title":"Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes","volume":"27","author":"Colombo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.011_bib56","doi-asserted-by":"crossref","first-page":"257695","DOI":"10.1155\/2012\/257695","article-title":"Cancer\/testis antigen MAGE-C1\/CT7: new target for multiple myeloma therapy","volume":"2012","author":"de Carvalho","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.clml.2018.02.011_bib57","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1182\/blood-2006-05-024661","article-title":"Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications","volume":"109","author":"Gonzalez-Paz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib58","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/cncr.20295","article-title":"DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies","volume":"100","author":"Seidl","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.011_bib59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib60","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3324\/haematol.2013.093500","article-title":"Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"99","author":"Kubiczkova","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.02.011_bib61","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/bjc.2012.525","article-title":"Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma","volume":"107","author":"Jones","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2018.02.011_bib62","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2018.02.011_bib63","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s11427-015-4969-2","article-title":"The role of circulating miRNAs in multiple myeloma","volume":"58","author":"Zhang","year":"2015","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.clml.2018.02.011_bib64","first-page":"578","article-title":"Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"25","author":"Kyle","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2018.02.011_bib65","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.011_bib66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undeterminedsignificance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2018.02.011_bib67","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.clml.2017.06.022","article-title":"Smoldering multiple myeloma: who and when to treat","volume":"17","author":"Mateos","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.02.011_bib68","article-title":"The road to cure in multiple myeloma starts with smoldering disease","volume":"3","author":"Salem","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.clml.2018.02.011_bib69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"Sawyer","year":"2011","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clml.2018.02.011_bib70","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction\u00a0and\u00a0post-transplantation consolidation therapies","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017314015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017314015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:10Z","timestamp":1761870610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017314015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S2152265017314015"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}